BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20230101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241001
DTEND;VALUE=DATE:20241004
DTSTAMP:20260515T144717
CREATED:20240522T154559Z
LAST-MODIFIED:20240829T193857Z
UID:39134-1727740800-1727999999@www.pharmajournalist.com
SUMMARY:6th Macrophage-Directed Therapies Summit
DESCRIPTION:Learning From the Past & Spearheading Macrophage Clinical Acceleration \nThe 6th Macrophage-Directed Therapies Summit is uniting 60+ biopharma and academia leaders across R&D\, Discovery\, Biology\, Translational\, and Clinical Development fields for invaluable networking and insights into all facets of macrophage-directed therapies. \nGrab your Full Agenda – https://ter.li/nqf2qd \nDespite toxicity concerns for CD47 targets in 2023\, the macrophage community persists in exploring innovative targets. Their determination to unveil new data showcasing safety and proof of concept remains stronger than ever\, revitalizing momentum in this highly promising industry. \nThis October\, you could meet leading experts from Verseau Therapeutics\, Inceptor Bio\, Carisma Therapeutics\, Elpiscience Biopharmaceuticals\, John Hopkins School of Medicine\, Resolution Therapeutics\, and more\, offering exclusive insights into their winning strategies for staying ahead of the curve in the years ahead. \nKey Highlights: \n\nTackling challenges in delivery\, administration\, animal model selection\, reprogramming\, manufacturing\, and more to optimize choices\nExploring indications for extending beyond oncology to autoimmunity\, inflammation\, neurodegenerative diseases\, and beyond\nAssessing the evolving macrophage-therapeutics landscape to uncover innovative targets and the latest data\n\nRegister Here for the Best Savings – https://ter.li/o22pxt
URL:http://www.pharmajournalist.com/event/6th-macrophage-directed-therapies-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241001
DTEND;VALUE=DATE:20241004
DTSTAMP:20260515T144717
CREATED:20240530T075147Z
LAST-MODIFIED:20240719T125600Z
UID:39187-1727740800-1727999999@www.pharmajournalist.com
SUMMARY:4th iPSC Drug Development & Manufacturing Summit
DESCRIPTION:With Kenai Therapeutics emerging from stealth with an $82 Million Series A funding round\, 2024 has started strong for iPSC drug developers looking to showcase the potential of their pipelines ahead of the next wave of investment. Introducing the 4th iPSC Drug Development & Manufacturing Summit\, your longest standing and definitive iPSC focused platform. \nNo iPSC stone will be left unturned\, as key industry experts including Kenai Therapeutics\, Cytovia Therapeutics\, Aspen Neuroscience\, NIST and many more\, unite under one roof to transform the future of iPSC cell therapies. For the first time in 4 years\, uniting R&D teams\, manufacturing experts and business leaders\, across 2 tracks of content for 3-days of cutting edge data presentations and strategic cross-functional discussions. Take a look at the full session details today. \nWith all this and more\, don’t miss this golden opportunity to help you and your entire team stay at the forefront of the iPSC cell therapy revolution!
URL:http://www.pharmajournalist.com/event/4th-ipsc-drug-development-manufacturing-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241014
DTEND;VALUE=DATE:20241016
DTSTAMP:20260515T144717
CREATED:20240613T152904Z
LAST-MODIFIED:20240613T152904Z
UID:39260-1728864000-1729036799@www.pharmajournalist.com
SUMMARY:Wearable Injectors and Connected Devices UK
DESCRIPTION:SAE Media Group’s 5th Annual Wearable Injectors and Connected Devices Conference will explore on-body device design and development whilst also engaging in the latest advances in connectivity and digital health applications for wearable devices with industry perspectives from big pharma representatives. The conference will consider key developments in the wearable injectors field\, including the enhanced demand for on-body injectors and digitalised health as the need for at home self-administration and routes for delivery of time-dependent\, high volume and viscous drugs grow. \n \nThe conference will also cover key regulatory updates such as guidance on MDR requirements from regulatory and notified bodies\, and the importance of considering user-experience and developing patient-centric devices. The two-day conference will bring you high-quality insights and industry connections on the latest advances in wearable injectors and connectivity\, and a platform for exchanging ideas. \nWhy  attend: \n\n2 full days of networking opportunities.\n16+ sessions with 75% of speakers from big pharma companies.\nAn agenda designed for professionals within the injectables space\, focused on the development\, implementation and application of wearable injectors and connected devices.\nThe only conference discussing wearable injectors and connected devices together\, other than our USA version of this event.\n\nThe Experience: \n\nA collaborative environment for pharma\, biotech and device developers to discuss the latest trends and challenges within the wearable injectors and connected device market.\nLearn from key industry players about new technologies\, strategies and processes for the development of wearable injectors.\nGain insights into the regulatory processes for the approval of wearable injectors and develop a greater understanding of how-to bring devices to market.\nCreate a dialogue with industry leaders and develop a network with the key stakeholders in the market.\nDelve into the world of digital health for the healthcare sector and discuss implementation of connectivity with on-body drug delivery systems.\nExamine the importance of usability for at home injectors\, and what is needed to make a device appropriate for patient administration.
URL:http://www.pharmajournalist.com/event/wearable-injectors-and-connected-devices-uk/
LOCATION:London\, UK
ORGANIZER;CN="SAE Media Group":MAILTO:events@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241015
DTEND;VALUE=DATE:20241017
DTSTAMP:20260515T144717
CREATED:20240607T121643Z
LAST-MODIFIED:20240607T121643Z
UID:39244-1728950400-1729123199@www.pharmajournalist.com
SUMMARY:Reuters Events: Pharma & Patient USA 2024
DESCRIPTION:Are you listening to your patient community? It’s not enough. Standing in the shadows and harvesting anecdotal insights won’t build connections\, create first-hand knowledge or illuminate your impact to internal stakeholders. \n \nWe must step forward and be visible\, actively engaging in patient communities and embedding the patient voice internally. YOU are the patient advocate in your company\, so overturn tokenistic gestures into meaningful actions that prioritise patients over patents. \nThis starts now. You must integrate and co-create from the outset\, from clinical design to commercial execution to boost adherence\, trial participation and create exceptional outcomes. Show that pharma is driven by more than profit – to build a world that empowers all patients and leaves no one in the dark. THIS is the real value of your work. \nWelcome to Pharma & Patient USA\, the co-created event for patient champions in pharma\, who won’t sit back. This October you will engage with leading pharma executives and patient advocates to learn first-hand how to drive change that will build a brighter and more inclusive future in healthcare. \nAre you ready to be the new beacon of trust? Join us to be in the room\, be visible and be engaged.
URL:http://www.pharmajournalist.com/event/reuters-events-pharma-patient-usa-2024/
LOCATION:Westin Boston Seaport\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Reuters Events":MAILTO:kana.hutton@thomsonreuters.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241022
DTEND;VALUE=DATE:20241025
DTSTAMP:20260515T144717
CREATED:20240524T114253Z
LAST-MODIFIED:20240719T125514Z
UID:39167-1729555200-1729814399@www.pharmajournalist.com
SUMMARY:6th Annual TIL Therapies Summit
DESCRIPTION:Following the watershed approval of Iovance’s Lifileucel\, all eyes are now on TIL therapies as the up-and-coming major therapeutic avenue for solid tumor treatment. Introducing the 6th Annual TIL Therapies Summit! With 30+ expert speakers\, 12 new speaker companies\, 2 brand-new content-filled tracks and 2 brand-new interactive workshops\, you won’t want to miss out! \nHear from TIL industry leaders like Iovance\, MD Anderson Cancer Center\, Obsidian Therapeutics\, Steven Rosenberg’s group from the National Institute of Health and more\, as they share ground-breaking TIL discoveries from R&D to commercialization. \nJoin us in October to capitalize on this golden opportunity to ensure you and your entire team stay ahead of the TIL wave!
URL:http://www.pharmajournalist.com/event/6th-annual-til-therapies-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241022
DTEND;VALUE=DATE:20241025
DTSTAMP:20260515T144717
CREATED:20240805T120043Z
LAST-MODIFIED:20240805T120043Z
UID:39495-1729555200-1729814399@www.pharmajournalist.com
SUMMARY:5th CFC Summit
DESCRIPTION:The 5th Commercializing Flow Chemistry Summit marks a pivotal year\, introducing a significant shift in content to address the evolving needs of the pharmaceutical manufacturing industry. This summit zeroes in on advanced scale-up capabilities and stakeholder engagement strategies\, responding to a market that is rapidly expanding and forecasted to reach US $4.6 billion by 2032. Attendees will delve into specialized sessions that focus on late–stage process development\, enhanced regulatory compliance\, and innovative manufacturing techniques like electrochemistry and continuous processing. \nThis event is crucial for professionals aiming to stay ahead in an industry moving towards more sustainable and efficient production methods. With a fresh emphasis on practical\, application-focused content\, the summit provides essential insights and networking opportunities\, making it a must-attend event for those looking to drive technical and strategic decision-making in their organizations. \nTo know more visit: https://ter.li/wiczxd
URL:http://www.pharmajournalist.com/event/5th-cfc-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241028
DTEND;VALUE=DATE:20241031
DTSTAMP:20260515T144717
CREATED:20240718T090741Z
LAST-MODIFIED:20240924T114834Z
UID:39393-1730073600-1730332799@www.pharmajournalist.com
SUMMARY:Cell & Gene Therapy Regulatory Affairs Summit
DESCRIPTION:𝘞𝘢𝘯𝘵 𝘵𝘰 𝘜𝘯𝘥𝘦𝘳𝘴𝘵𝘢𝘯𝘥 𝘎𝘶𝘪𝘥𝘢𝘯𝘤𝘦\, 𝘚𝘵𝘳𝘦𝘢𝘮𝘭𝘪𝘯𝘦 𝘚𝘶𝘣𝘮𝘪𝘴𝘴𝘪𝘰𝘯𝘴\, & 𝘖𝘣𝘵𝘢𝘪𝘯 𝘈𝘱𝘱𝘳𝘰𝘷𝘢𝘭? \nThe knowledge and connections you gain at the 𝗖𝗲𝗹𝗹 & 𝗚𝗲𝗻𝗲 𝗧𝗵𝗲𝗿𝗮𝗽𝘆 𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗔𝗳𝗳𝗮𝗶𝗿𝘀 𝗦𝘂𝗺𝗺𝗶𝘁 will make the difference between success and delay in your IND and BLA applications. You’ll hear from top regulatory experts like David Uguen (𝗢𝗿𝗰𝗵𝗮𝗿𝗱 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀)\, Shirley Bartido (𝗧𝗮𝗸𝗲𝗱𝗮 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹𝘀)\, Yao-Yao Zhu (𝗔𝘀𝘁𝗿𝗮𝗭𝗲𝗻𝗲𝗰𝗮)\, and many more. \n  \n𝗘𝘅𝗽𝗹𝗼𝗿𝗲 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗯𝗿𝗼𝗰𝗵𝘂𝗿𝗲 𝗵𝗲𝗿𝗲 – https://ter.li/8bp1bf \nIn the fast-evolving world of cell and gene therapy\, staying ahead of regulatory changes is critical. The stakes are high\, and your applications need to be flawless to speed up approval and bring life-saving therapies to patients faster. \nThe 𝗖𝗲𝗹𝗹 & 𝗚𝗲𝗻𝗲 𝗧𝗵𝗲𝗿𝗮𝗽𝘆 𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗔𝗳𝗳𝗮𝗶𝗿𝘀 𝗦𝘂𝗺𝗺𝗶𝘁 will offer you the chance to: \n\nStay updated on evolving regulatory guidance\nLearn from real-world case studies\nExplore new CMC guidance\n\n… and more! \n𝗦𝗲𝗲 𝗮𝗹𝗹 𝗼𝗳 𝘄𝗵𝗮𝘁 𝘁𝗵𝗶𝘀 𝗲𝘃𝗲𝗻𝘁 𝗵𝗮𝘀 𝘁𝗼 𝗼𝗳𝗳𝗲𝗿 𝗶𝗻 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗮𝗴𝗲𝗻𝗱𝗮 – https://ter.li/8bp1bf \nDon’t miss out on your chance to navigate the complex regulatory landscape and accelerate your therapeutic pipelines at this meeting!
URL:http://www.pharmajournalist.com/event/cell-gene-therapy-regulatory-affairs-summit/
LOCATION:Washington Marriott Capitol Hill\, 175 L St NE\, Washington\, WA\, 20002\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241028
DTEND;VALUE=DATE:20241101
DTSTAMP:20260515T144717
CREATED:20240807T112944Z
LAST-MODIFIED:20240807T113009Z
UID:39511-1730073600-1730419199@www.pharmajournalist.com
SUMMARY:7th TPD & Induced Proximity Summit
DESCRIPTION:With a flurry of high capital collaborations and partnership deals from the likes of C4T\, Merck KgGA\, Monte Rosa\, Proxygen\, Orum\, and momentum building in clinic with BTK degraders\, ER degraders and many more assets. It has never been more import to re-join forces at the 7th TPD & Induced Proximity Summit\, the longest standing and most comprehensive protein degradation and proximity based conference. \nSpanning foundational research and discovery\, through to IND-filing and clinical trials\, this is the world’s definitive meeting to discuss opportunities and challenges the TPD & Induced Proximity field must address to expand the target space and facilitate the discovery and development of therapeutically relevant degraders\, blockers\, stabilizers and inducers of protein-protein interactions. Whether you’re entering the space for the first time or a well-seasoned TPD veteran\, this forum will equip you with the knowhow and connections to make rapid advances in your work. \nThe 85+ industry expert speakers include: \n\nAlessio Ciulli\, Founder & Director\, Centre for Targeted Protein Degradation (University of Dundee)\nStuart Schreiber\, Founding Chief Executive Officer\, Arena Bioworks\nSharon Townson\, Chief Scientific Officer\, Monte Rosa Therapeutics\nNello Mainolfi\, Founder\, President & Chief Executive Officer\, Kymera Therapeutics\nAdrian Gottschalk\, Chief Executive Officer\, Foghorn Therapeutics\nAndrew Hirsch\, Chief Executive Officer\, C4 Therapeutics\nArthur T. Sands\, Chief Executive Officer\, Nurix Therapeutics\nChinatsu Sakata-Sakur\, Vice President\, Astellas Pharma\n\nAssembling over 500 TPD & Induced Proximity enthusiasts from across every corner of the landscape\, we have left no stone unturned to deliver the full breadth and depth of protein degradation and modulation research with SureTACs\, EpiTACs\, RIPTACs\, Molecular Gates\, and so much more. \nView the agenda here: https://ter.li/8nvx3c
URL:http://www.pharmajournalist.com/event/7th-tpd-induced-proximity-summit/
LOCATION:The Westin Copley Place\, 10 Huntington Avenue\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241030
DTEND;VALUE=DATE:20241102
DTSTAMP:20260515T144717
CREATED:20240719T115454Z
LAST-MODIFIED:20240719T115454Z
UID:39424-1730246400-1730505599@www.pharmajournalist.com
SUMMARY:6th Gene Therapy Analytical Development & CMC Summit
DESCRIPTION:Twelve gene therapies have been approved by the FDA to date to treat a variety of diseases\, including the first ever gene edited therapeutic. The CMC package required to effectively demonstrate safety and efficacy of increasingly complex gene therapy products to regulators needs to keep pace. \nThe 6th Gene Therapy Analytical Development & CMC Summit will unite 250+ analytical development\, CMC\, QC\, and process development experts to showcase innovative analytical and process development methods\, assess their readiness\, and ultimately guarantee safety\, quality\, efficacy\, and consistency of gene therapies to regulators. \nVIEW THE FULL EVENT GUIDE \nJoin your peers this July to: \n\nUnderstand how to transition your potency assay from early to late-stage\nExplore how NGS methods can better inform your genome titers\nAccurately measure partials in your samples\nProduce contaminant-free and high yield vector batches at scale\n\nSecure your place here or get in touch with the team – info@hansonwade.com
URL:http://www.pharmajournalist.com/event/6th-gene-therapy-analytical-development-cmc-summit/
LOCATION:The Westin Copley Place\, 10 Huntington Avenue\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com or Partnership Enquiries: sponsor@hansonwade.com
END:VEVENT
END:VCALENDAR